Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase
- 147 Downloads
Imatinib is a first-line tyrosine kinase inhibitor for treating chronic myelogenous leukaemia (CML) and has greatly improved the prognosis of this disease. An increasing number of CML patients of reproductive age are diagnosed each year, and the impact of imatinib on fertility is a major concern. Providing useful advice to these patients regarding the choice of their therapeutic treatment is very important.
This study examined the impact of imatinib on the fertility of male patients with CML in the chronic phase.
Patients and Methods
We performed a study of 48 adult male CML patients in the chronic phase (CML-CP), 50 healthy control subjects, and 10 male patients with infertility. Imatinib levels in semen and plasma were measured using high-performance liquid chromatography/mass spectrometry. We examined the effects of imatinib on sperm parameters and the male reproductive system using a computer-assisted sperm assay and ultrasound, respectively. We analysed sex hormone levels in the sera of CML-CP patients using an enzyme-linked immunosorbent assay.
Imatinib levels in semen were comparable to plasma levels in CML-CP patients. CML-CP patients treated with imatinib exhibited reduced sperm density, counts, survival rates, and activity. Ultrasound demonstrated that the shape and size of the testis and epididymis in CML-CP patients undergoing imatinib treatment were normal. However, 19 of these patients exhibited a hydrocele in their tunica vaginalis, with a large dark area of effusion (0.7–2.9 cm in width). Sex hormone levels in the sera of the CML-CP patients were normal.
Compliance with Ethical Standards
This study was supported by a grant from the National Nature Science Foundation of Liaoning Province (number: 2,015,020,411–301).
Conflict of Interest
The authors declare no conflicts of interest.
- 2.Avilésvázquez S, Chávezgonzález A, Mayani H. Tyrosine kinase inhibitors (TKI): a new revolution in the treatment of chronic myeloid leukemia (CML). Gac Med Mex. 2013;149(6):646–54.Google Scholar
- 4.Sacha T. Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis. 2014;6(1):e2014007.Google Scholar
- 8.Fava C, Rege-Cambrin G, Saglio G. The choice of first-line chronic myelogenous leukemia treatment. Ann Hematol. 2015;94(2):S123–31.Google Scholar
- 11.XiaoHui C, Huai G, Yang X. Imatinib effects on fertility and reproductive in patients with chronic myelogenous leukemia (in Chinese, review). Carcinog Teratog Mutagen. 2010;22(6):477–9.Google Scholar
- 14.Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med. 2004;351(20):2134–5.Google Scholar
- 21.Jain A, Khadwal A, Prakashet G, al. Cytopathological diagnosis of an unusual cause of malignant Hydrocele. Clin Medicine Insights Pathol. 2016;9(9):29–31.Google Scholar
- 23.Seymour JF, Grigg A, Reynolds J, et al. Imatinib’s potential effects on fertility, immunity and pulmonary function: a prospective study in patients with previously untreated CML. Blood. 2004;104(11):1020.Google Scholar
- 24.Xiaohui C, Huai G, Yubin C, et al. One case report: a male patient with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies [article in Chinese]. Zhong Guo Yi Yao Dao Bao. 2013;10(1):116–7.Google Scholar